Medicenna Therapeutics' recent CPC transaction is featured in the Financial Post. Click on the image above for the article.
Tier 2 Canadian Healthcare Companies – same as Tier 1, not a good year In this blog, I am going to comment on the Q4 and annual 2016 share price performances of the group of 52 companies which ended 2016 in Tier 2 (there were 58 companies with share prices of $1.00 or more to [...]
Tier 1 Canadian Healthcare Companies – not a good year In this blog, I am going to comment on the Q4 and 2016 annual performances of the group of 51 companies which ended 2016 in Tier 1 (there were 57 companies with share prices of $1.00 or more to start 2016). Q4 2016 Performance [...]
For the analysis of the 2016 share price performance for the Canadian healthcare sector, there were 115 companies starting 2016 with share prices of $0.10 or higher. Twelve of these companies were no longer in the sector by the end of 2016, with six lost through acquisition/merger transactions. For the remaining 103 companies, the sector [...]
Don’t Cross That Line – Contradictions in Provincial Pharmacare I’m in the middle of moving from Nova Scotia to Prince Edward Island and all that entails. I am aware that we’re fiercely proud of our provincial cultural differences here in the Maritimes (try debating who has the best lobster) so I expect a few things [...]
Tier 2 Canadian Healthcare Companies – better performance than the Tier 1 companies In this blog, I am going to comment on the Q3 and 9-month 2016 share price performance of the group of 57 companies with share prices of between $0.10 and $0.99 to start 2016 (DiagnoCure is not included). Advancers outnumbered decliners [...]
Tier 1 Canadian Healthcare Companies – a very healthy bounce back In this blog, I am going to comment on the Q3 and 9-month performances of the group of 54 companies with share prices of $1.00 or more to start 2016 (Stellar Biotechnologies, Prism Medical and Transition Therapeutics dropped from assessment). Advancers outnumbered decliners [...]
Improved, positive performance in Q3 Overall, Q3 2016 share price performance in the sector was much better than in Q2 for the companies starting 2015 with share prices of $0.10 or higher. Two more companies have been deleted from the analysis in Q3 – Transition Therapeutics was acquired by OPKO Health and Prism Medical was [...]
TORONTO, September 6, 2016 - Bloom Burton & Co. Limited (“Bloom Burton”), Canada’s leading healthcare-specialized investment banking firm, is pleased to announce the appointment of Shawn Aspden as Managing Director of the firm. Mr. Aspden, CFA®, is a highly respected 20-year veteran of the Canadian capital markets, having most recently served as Vice Chairman and [...]
Check out the CTI Life Sciences Fund's Janelle Anderson's interview of Brian Bloom on the Human Proof Of Concept podcast by clicking on the image below.